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Abstract
Fungal diseases still play a major role in morbidity and mortality in patients with haematological malignancies, including those undergoing hae-
matopoietic stem cell transplantation. Although Aspergillus and other ﬁlamentous fungal diseases remain a major concern, Candida infections are
still a major cause of mortality. This part of the ESCMID guidelines focuses on this patient population and reviews pertaining to prophylaxis,
empirical/pre-emptive and targeted therapy of Candida diseases. Anti-Candida prophylaxis is only recommended for patients receiving allogeneic
stem cell transplantation. The authors recognize that the recommendations would have most likely been different if the purpose would have
been prevention of all fungal infections (e.g. aspergillosis). In targeted treatment of candidaemia, recommendations for treatment are available
for all echinocandins, that is anidulafungin (AI), caspofungin (AI) and micafungin (AI), although a warning for resistance is expressed. Liposomal
amphotericin B received a BI recommendation due to higher number of reported adverse events in the trials. Amphotericin B deoxycholate
should not be used (DII); and ﬂuconazole was rated CI because of a change in epidemiology in some areas in Europe. Removal of central venous
catheters is recommended during candidaemia but if catheter retention is a clinical necessity, treatment with an echinocandin is an option (CIIt).
In chronic disseminated candidiasis therapy, recommendations are liposomal amphotericin B for 8 weeks (AIII), ﬂuconazole for >3 months or
other azoles (BIII). Granulocyte transfusions are only an option in desperate cases of patients with Candida disease and neutropenia (CIII).
Keywords: Candida, European, guideline, haematopoietic stem cell transplantation, malignancies
Clin Microbiol Infect 2012; 18 (Suppl. 7): 53–67
Corresponding author: A. J. Ullmann, Infectious Diseases, Department of Internal Medicine II, Julius-Maximilians-University, Oberdu¨rrbacher Str. 6,
97080 Wu¨rzburg, Germany
E-mail: andrew.ullmann@uni-wuerzburg.de
This guideline was presented in part at ECCMID 2011.
*European Society for Clinical Microbiology and Infectious Diseases.
Members of the subgroup committee mainly responsible for this manuscript.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ESCMID PUBLICATIONS 10.1111/1469-0691.12041
Introduction
Infectious complications remain a major obstacle in the suc-
cessful treatment of patients with malignant diseases. This
part of the ESCMID guidelines focuses on the special need of
this patient population with malignancies that had received
chemotherapy or radiotherapy. Candida diseases played a piv-
otal role in the past in patients with malignancies [1–3]. In an
Italian study, patients with AML and ALL developed candida-
emia at incidence rates of 2–3% and 4–5%, respectively [4].
In one German hospital, candidaemia remains a disease with
a high fatality rate [5]. Studies report an overall mortality
risk as high as 38% with an attributable mortality of 19% [2].
Risk factors such as previous triazole exposure, age, high AP-
ACHEII scores, renal failure and neutropenia contribute to
these high mortality rates [2,6]. A change in the Candida spe-
cies epidemiology also needs special attention since ﬂuconaz-
ole sensitive C. albicans is not the sole cause of disease [2,7].
Therefore, Candida diseases deserve special attention in this
high-risk population. We included recommendations for hae-
matopoietic stem cell transplant recipients, which is an inte-
gral part of the guideline. This guideline is divided into four
parts: prophylaxis, pre-emptive/empirical therapy strategies,
targeted treatment and speciﬁc situations in patients with
malignancies.
Numerous guidelines have been published to date and
have usually included all fungal diseases [8–11]. Here, we
focus on Candida diseases with diagnostic procedures
and recommendations for treatment. This guideline was
originally edited as described previously by the ﬁrst 4
authors and later reviewed and edited by the entire
EFISG (ESCMID Fungal Infection Study Group) guideline
group [155].
Other fungal diseases, for example aspergillosis in this
patient population will also need special attention. The
authors recognize that other ﬁlamentous fungal infections
besides aspergillosis play a more pivotal role in the morbid-
ity and mortality in this patient population (e.g. agents of
mucormycosis) [12–16]. Therefore, the recommendations
for prophylaxis and empirical/pre-emptive therapy would
possibly direct our guideline recommendation in a different
direction because this guideline focuses solely on Candida
diseases.
The same grading system for the strength of recommen-
dation and its documented quality of evidence are used
throughout of this guideline as in the majority of the EFISG
guidelines. The explanations and abbreviations used in this
document are given in Table 1.
Anti-Candida prophylaxis in allogeneic
haematopoietic stem cell transplantation
The intention of the EFISG recommendations for prophylaxis
in allogeneic haematopoietic stem cell transplantation is to
look at the possibility of reducing morbidity and mortality
due to Candida diseases. Obviously, the authors recognize
that the recommendations would have been signiﬁcantly dif-
ferent if the purpose would have been prevention of all fun-
gal infections (e.g. aspergillosis). The prescribing physician
should be aware of these interpretations. Different immune
deﬁcient situations, often referred to as the ‘net state of
immunosuppression’, need to be appreciated during the
course of allogeneic haematopoietic stem cell transplantation
[17]. During the early post-transplantation phase, neutrope-
nia is a major ﬁnding in these patients. Criteria for selecting
prophylaxis throughout the various phases after transplanta-
tion should be a low toxicity proﬁle and good efﬁcacy. For
the purpose of reducing morbidity, various antifungal agents
have similar outcomes as ﬂuconazole and have therefore
received a similarly strong recommendation. But the strength
of recommendation by the EFISG when including all possible
fungal infections (i.e. aspergillosis) would be most likely dif-
ferent.
For prevention during the early neutropenic phase after
transplantation, almost all available azoles are scored as
highly recommended. Indeed, several publications demon-
strated a reduction in morbidity for Candida diseases [18–
23]. Later studies utilized voriconazole in comparison with
itraconazole or ﬂuconazole as comparators [24,25]. Despite
TABLE 1. Strength of the EFISG Recommendation and
Quality of Evidence. Two parts: Strength of a
Recommendation (SoR) and Quality of Evidence (QoE)
Strength of a recommendation
Grade A ESCMID strongly supports a recommendation for use
Grade B ESCMID moderately supports a recommendation for use
Grade C ESCMID marginally supports a recommendation for use
Grade D ESCMID supports a recommendation against use
Quality of Evidence
Level I Evidence from at least one properly designed randomized,
controlled trial
Level II* Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case-controlled analytic
studies (preferably from >1 centre); from multiple time
series; or from dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on
clinical experience, descriptive case studies, or reports of
expert committees
*Added index:
r: Meta-analysis or systematic review of randomized controlled trials.
t: Transferred evidence, that is, results from different patients’ cohorts, or
similar immune-status situation.
h: Comparator group is a historical control.
u: Uncontrolled trial.
a: Published abstract (presented at an international symposium or meeting).
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the absence of noninferiority testing in the recent voriconaz-
ole trials, an equal outcome compared with ﬂuconazole is
assumed and therefore voriconazole received an AI recom-
mendation for the prevention of Candida disease. Posaconaz-
ole was not tested in a trial during the early phase of
allogeneic haematopoietic stem cell transplantation but the
duration and severity of neutropenia is very similar to that
observed during induction chemotherapy for AML therapy
[26]. Because of this implied evidence, posaconazole received
an AIIt recommendation. Micafungin and caspofungin were
the only echinocandins so far assessed in prophylaxis and
demonstrated similar efﬁcacy to ﬂuconazole in transplant
recipients [27]. Chou et al. used caspofungin in allogeneic
stem cell recipients. In this retrospective study, 7.3% of the
123 patients developed a fungal disease. Two of the nine
cases with fungal disease were Candida tropicalis and Candida
glabrata infections [28].
In addition to the early neutropenic phase, another time
period plays historically an important role after allogeneic ha-
ematopoietic stem cell transplantation, that is, the ﬁrst
100 days after transplantation. During this period, patients
are also prone to fungal diseases but not all antifungal agents
(e.g. micafungin and posaconazole) have been tested during
this period [27]. Historically, a few azoles were able to
reduce morbidity and mortality, especially fungal-attributable
mortality, during this phase [18,19]. However, other trials
examined the value of prophylaxis beyond the neutropenic
phase to include this ﬁrst 100 days period. As for the vorico-
nazole prophylaxis trial that was performed during the ﬁrst
100 days after transplantation, it had a similar outcome to
ﬂuconazole [24]. Therefore, the AI recommendation with
the intention to reduce morbidity in invasive candidiasis is
ascribed to voriconazole and ﬂuconazole. In the well-known
trials by Goodman et al. [18] and Slavin et al. [19], survival
advantage was driven by reduced mortality to Candida dis-
ease. In the trial performed by Marr et al. [22], itraconazole
demonstrated superiority to ﬂuconazole but no mortality dif-
ference was noted. Itraconazole was associated with signiﬁ-
cantly more toxicity and this explains a weaker strength of
recommendation for itraconazole than ﬂuconazole. It
remains unclear whether patients without GVHD and recov-
ered neutrophils need anti-Candida prophylaxis during the
ﬁrst 100 days after transplantation.
Another important intention for the outcome of patient
care is the survival advantage when using antifungal agents as
prophylaxis. Again, during the early phase of neutropenia, all
azoles except ﬂuconazole received a lower recommendation
(C). During the ﬁrst 100 days after transplantation, only
ﬂuconazole compared with placebo was able to demonstrate
a survival advantage in Candida diseases [18,19]. Both vorico-
nazole trials did not demonstrate any mortality difference
[24,25]. The overall death rate in the Cornely et al. [26] trial
was signiﬁcantly lower in patients with posaconazole, and
therefore, posaconazole received a slightly stronger grade of
recommendation. Finally, during moderate to severe graft-
versus-host disease, posaconazole received a weaker BI rec-
ommendation. In the Ullmann et al. [29] trial, posaconazole
had an identical outcome regarding Candida infection com-
pared with ﬂuconazole, but the rate of fungal-related death
was lower with posaconazole and consequently posaconazole
received a slightly higher recommendation, although the Can-
dida-associated death rate was not clear. The association
between intention and the dosage of the intervention, includ-
ing strength of recommendation, are noted in Table 2.
Another important scenario of immunosuppression plays a
signiﬁcant role in the outcome in the transplant recipient.
Due to increased immunosuppressive therapy during the lat-
ter phase (beyond 100 days) in patients with graft-versus-
host disease, slow T-cell recovery and increased risk of fun-
gal infections is obvious. The trial by Ullmann et al. [29] dem-
onstrated that posaconazole and ﬂuconazole were equally
efﬁcacious in preventing candida infections. Other drugs
were rated weaker (Table 2). Itraconazole and amphotericin
B deoxycholate received a weaker recommendation because
of a weaker safety proﬁle [22,30–32].
Anti-Candida prophylaxis in autologous
haematopoietic stem cell transplantation
and in severe and prolonged neutropenia
In the autologous transplant setting, only the neutropenic
phase can be considered a possible risk situation for Candida
diseases. But with the improvement of autologous transplan-
tation procedures over time, antifungal prophylaxis is not rec-
ommended for autologous transplantation recipients [33].
Nevertheless, in centres with a high incidence of Candida dis-
ease, prophylaxis could remain an option, but based on recent
data only a weak C recommendation is provided for itraco-
nazole and posaconazole (C) [26,34]. The group was not able
to provide a recommendation when antibody treatment is co-
administered (e.g. rituximab) due to the lack of data, and obvi-
ously, there seems to be no increased risk of fungal infections.
There is indirect evidence for a survival advantage in prophy-
laxis for invasive candida disease, which is only available from
the Cornely et al. [26] trial for patients with severe and pro-
longed neutropenia. None were studied with other drugs for
Candida disease in autologous stem cell recipients. In general,
autologous haematopoietic stem cell transplantation is not
considered a high-risk situation for patients.
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The treatment of numerous other malignant diseases
causes neutropenia in varying degrees of severity and dura-
tion. Prophylaxis in this patient population is usually adminis-
tered only if the patient develops profound and prolonged
neutropenia. Again, our group does not support prophylaxis
for the prevention of Candida diseases in this setting (pro-
phylaxis: DII).
In nontransplantat settings, all recommendations are very
similar to those for autologous transplantation. There is only
very weak evidence for the use of azole prophylaxis against
Candida diseases for the group of azoles. The study by
Glasmacher et al. [32] saw no difference between ﬂuconazole
and itraconazole. Another randomized placebo-controlled
study demonstrated the superiority of itraconazole for
TABLE 2. Anti-Candida prophylaxis for allogeneic haematopoietic stem cell recipients
Intention:Morbidity
reduction
Intention: Survival
improvement
ReferencesSoR QoE SoR QoE
Intervention (anti-Candidal prophylaxis) during the neutropenic phase
Fluconazole 400 mg qd if no prophylaxis is considered A I A I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid B I C I [22,23]
Posaconazole* 200 mg tid A IIt B IIt [26,29]
Voriconazole* 200 mg bid A I C I [24]
Caspofungin* 70/50 mg qd C IIu C III [28]
Micafungin* 50 mg qd A I C I [27]
Anidulafungin NR ND NR ND
Liposomal amphotericin B 50 mg every other day iv, 100 mg/weekly B II C III [38,39]
Intervention (anti-Candidal prophylaxis) during the ﬁrst 100 days without GVHD and neutrophil recovery
Fluconazole 400 mg qd A I A I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid B I C I [22,23]
Posaconazole* 200 mg tid C III C III [26,29]
Voriconazole* 200 mg bid A I C I [24]
Caspofungin* 70/50 mg qd C IIu C IIu [28]
Micafungin* 50 mg C III C III [27]
Anidulafungin NR ND NR ND
Liposomal amphotericin B 50 mg every other day iv, 100 mg/weekly C III C III [38,39]
Intervention (anti-Candidal prophylaxis) in GVHD
Fluconazole 400 mg qd A I C I [18–20,22,23]
Itraconazole* 2.5 mg/kg oral solution tid C I C I [22,23]
Posaconazole* 200 mg tid A I B I [29], equal outcome
regarding Candida
disease
Voriconazole* 200 mg bid B I C I [24] equal outcome
regarding Candida
disease
others NR ND NR ND ND
NR, no recommendation; ND, no data available.
*Decision was based on comparative trials with ﬂuconazole.
TABLE 3. Anti-Candida prophylaxis outside of allogeneic haematopoietic stem cell transplantation (e.g. autologous
haematopoietic stem cell transplantation or chemotherapy induced neutropenia)
Intention Situation
Autologous HCT Severe and prolonged neutropenia
ReferencesIntervention SoR/QoE Intervention SoR/QoE
Reduce morbidity and
mortality (during and
after high dose
chemotherapy)
Any prophylaxis DIII Any prophylaxis DIII [33]
Additional antibody
treatment (e.g.
rituximab)
Any prophylaxis DIII Any prophylaxis DIII
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*
Fluconazole ND Fluconazole CI For autologous
HCT: [26, 34]
For neutropenia:
[26, 32, 35-38, 40–43]
Itraconazole CII Itraconazole CI
Posaconazole CIIt Posaconazole CIIt
Voriconazole ND Voriconazole ND
Anidulafungin ND Anidulafungin ND
Caspofungin ND Caspofungin CI
Micafungin ND Micafungin ND
Nystatin DIIt Nystatin DII
Any amphotericin
B formulation
ND Any amphotericin
B formulation
DI
*If an institution wishes prophylaxis, weak recommendations for selected antifungal agents are provided.
ND, no data.
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preventing superﬁcial fungal infection in patients with haema-
tological malignancies and neutropenia [35]. Only one study
by Menichetti et al. [36] demonstrated a signiﬁcant lower
incidence of fungaemia due to Candida species in 0.5% of itr-
aconazole recipients and in 4% of placebo recipients, a differ-
ence of 3.5 percentage points (95% CI, 0.5–6%; p <0.01).
Obviously, no overall survival advantage in Candida-associated
mortality was noted.[36,37] In the trial by Penack et al. [38],
low dose of liposomal amphotericin B did not signiﬁcantly
prevent Candida infections. In a similar but smaller trial by
Cordonnier et al. [39], only one of twenty-nine patients
developed probable Candida disease. Other trials utilized var-
ious comparators (e.g. amphotericin B/nystatin or ﬂuconazole
vs. itraconazole), but none demonstrated superiority [40,41].
Nystatin, an oral polyene, cannot be recommended as pro-
phylaxis [42]. Only one retrospective trial where micafungin
was assessed as prophylaxis led to a signiﬁcant decrease in
the occurrence of IFI (from 12.3% to 1.5%, p 0.001) [43]
(Table 3).
Secondary prophylaxis is not indicated in cases of prior
candidaemia without any sign of deep-seated infection when
patients are exposed to a new immunosuppressive therapy
or where prolonged neutropenia is induced by chemother-
apy, autologous or allogeneic HCT. The strength of recom-
mendation for secondary prophylaxis in patients with a
history of deep-seated invasive Candida disease (not candida-
emia alone) was rated C III.
Empiric or pre-emptive (diagnostic driven)
antifungal therapy
In patients expected to suffer prolonged duration of neutro-
penia [>10 days] (induction and consolidation chemotherapy
of AML/MDS and autologous, or allogeneic transplantation)
fever occurs frequently and is usually treated primarily with
broad-spectrum antibacterial agents. If the patient does not
defervesce after at least 3–4 days of antibacterial treatment,
the presence of an undetected fungal infection is assumed
and antifungal therapy is usually added with the intention of
preventing further morbidity or death (AII) [44]. Extensive
diagnostic workup is required to exclude a clinically or
mycological documented infection which might require spe-
ciﬁc therapy.
Again, similar to the prophylactic indication, a challenge in
providing recommendations was the fact that empirical treat-
ment is not only given for the intention of treating as early
as possible an undetected Candida disease, but also any kind
of fungal infection (e.g. ﬁlamentous fungal infections). With
regards to a reduction in morbidity, liposomal amphotericin
B and caspofungin received an AI recommendation [44–47]
(Table 4). Voriconazole failed to demonstrate noninferiority
when compared to liposomal amphotericin B but in a subset
analysis of high-risk patients no differences were noted [48].
In a prospective but one-armed trial with micafungin, not a
single patient receiving empiric treatment developed a break-
through fungal infection [49]. In a retrospective trial compar-
ing micafungin and caspofungin, breakthrough Candida
diseases were detected at a rate of 0.7% and 2.8%, respec-
tively [50]. Amphotericin B deoxycholate and ﬂuconazole
were not recommended for empirical treatment despite the
existence of adequate studies in the past, because of toxicity
in the ﬁrst case, and narrow spectrum of action in the sec-
ond case [51–53]. The differences in the grading of ampho-
tericin B formulations lie solely in the different toxicity
proﬁles [54–56]. Amphotericin B colloidal dispersion causes
infusion-related events similar in frequency and intensity to
amphotericin B deoxycholate and in a direct double-blind
comparison trial amphotericin B lipid complex was more
toxic than liposomal amphotericin B [54,55]. The use of itr-
aconazole provided some promising results in a noncompara-
tor trial and in a recent published trial compared with
amphotericin B [56,57]. In the latter trial, itraconazole had a
better outcome. The major limitation for ﬂuconazole was
TABLE 4. Empiric therapy to treat possible Candida disease: All situations causing severe and prolonged neutropenia
Intention Intervention
Allogeneic
HCT included SoR QoE References
Morbidity reduction Liposomal amphotericin B (3 mg/kg/day) Yes A I [44,45,47,55]
Caspofungin (70 mg on day 1 then 50 mg) Yes A I [46,47]
Amphotericin B colloidal dispersion (4 mg/kg/day) Yes C I [54]
Amphotericin B lipid complex (5 mg/kg/day) Yes B I [55]
Itraconazole (200 mg iv q12h on day 1 & 2 then 200 mg iv/day) ND B I [56,57]
Voriconazole (2 · 6 mg/kg on day 1 then 2 · 3 mg/kg/day)§ Yes B I [48]
Fluconazole (400 mg/day) ND C* I* [52,53]
Amphotericin B deoxycholate (0.5–1.0 mg/kg/day) Yes D IIt [44,54,56,57]
Micafungin (100 mg) Yes B II [49,50]
Anidulafungin ND NR No data
*Limited use since ﬂuconazole has no mould activity. Application requires appropriate work-up to rule out mould disease.
NR, no recommendation; ND, no data available, §, dosis according to trial [48].
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the lack of antimould activity. Therefore, if ﬂuconazole is
used, it remains essential to rule out a mould infection by
the Aspergillus galactomannan index (GMI) ELISA and chest
and sinus CT scan.
A consensus criteria deﬁning pre-emptive (sometimes also
called ‘diagnostic driven’) treatment of fungal infections in can-
cer patients does not exist. The term ‘pre-emptive treatment’
is associated more with ﬁlamentous fungi infections than with
Candida-associated diseases. This approach is not driven by
persistent fever or neutropenia but rather by galactomannan
antigen detection in serum and/or BAL ﬂuid or high-resolution
CT scan in high-risk patients [58]. The role 1,3-ß-D-glucan and
PCR testing for aspergillosis/candidiasis remains controversial
[59,60]. Whether or not any kind of inﬁltrate in the presence
of Aspergillus galactomannan should trigger antifungal therapy is
still debatable, although few experts would not add an antifun-
gal agent in all of these situations. Some experts wait for Asper-
gillus associated typical radiographic signs [halo, wedge shaped,
air crescent or cavity] before starting treatment [58]. Other
authors are more ﬂexible [61,62]. Basically, no recommenda-
tion can be given at this point on the choice between the
empirical and pre-emptive approach.
No clinical trial has been performed to compare antifungal
drugs for this indication, and therefore, no recommendation
can be made. The main studies which tested the pre-emptive
approach used liposomal or deoxycholate formulation of
amphotericin B or voriconazole [61–63]. As treating pre-
emptively should mean treating at an early phase of disease,
drugs approved for the treatment of fungal diseases might be
effective or at least should be evaluated.
In summary, no data exist regarding whether or not Candida
diseases can be managed by pre-emptive anti-Candida therapy.
If Candida disease is the main concern and the patient is not on
azole prophylaxis, then ﬂuconazole might be a good choice.
However, in contrast to the ICU setting, no trial has prospec-
tively assessed the role of Candida spp. colonization or 1,3-ß-
D-glucan in these patients [64]. 1,3-ß-D-glucan was assessed
previously in a meta-analysis by Lamoth et al. [65] The group
concluded that two consecutive positive antigen tests in
patients with haemato-oncological patients demonstrate a high
speciﬁcity, positive predictive value but a low sensitivity.
Therefore, the test needs to be combined with clinical and
radiological assessments and microbiological ﬁndings [65].
Mucosal oropharyngeal or oesophageal
candidiasis
Mucosal candidiasis does not play a signiﬁcant role for
morbidity or mortality in haematological malignancies. The
occurrence of oropharyngeal or oesophageal candidiasis is
more inconvenient than threatening for the patient and usu-
ally easy to treat. For a rapid response, oral azoles, for
example ﬂuconazole, are recommended (AI) [66]. Physicians
should keep in mind that azole-resistant Candida species can
be selected during therapy even without prolonged treat-
ment periods [67,68]. Other azoles can then be used [69–
74]. Topical polyenes treatment is recommended for mild
forms as in nonimmunocompromised patients [66,75–78].
Oral candidiasis with dysphagia and thoracic pain when
swallowing is suggestive of oesophageal involvement. In this
situation, topical treatment is not recommended (topical
polyene treatment for oesophagitis: DIII). Cases refractory
to ﬂuconazole can be treated with any other azole if MIC
tests suggest susceptibility [70,71,79–82]. In the event of
severe or refractory disease, intravenous antifungals such as
an echinocandin or liposomal amphotericin B might be indi-
cated [83–90] (Table 5). It is essential to identify the species
causing candidiasis to ensure susceptibility to the chosen
agent [91]. This is a minimum requirement in immune-com-
promised patients, because resistance might have developed
and a mixed aetiology might be possible.
Targeted treatment of invasive candidiasis/
candidaemia
Treatment of invasive candidiasis or candidaemia should
always focus on the success of treatment with improved sur-
vival. Once the diagnosis of candidaemia is established, blood
cultures should be drawn on a daily basis until negativity for
at least two consecutive samples (B I). Treatment should at
least continue for 14 days after the last positive blood cul-
ture [92]. Individuals who have negative blood cultures for
more than 14 days but remain neutropenic at approximately
day 28 (or are not expected to recover from neutropenia)
should be evaluated for the resolution of clinical signs and
symptoms including exclusion of endocarditis and endoph-
thalmitis by appropriate examination. But deﬁning an exact
and appropriate duration of therapy is still an issue of
debate.
It is recommended that for patients who are on prophy-
laxis that the class of drugs for antifungal treatment be chan-
ged (C III). In prospective trials, only a few neutropenic
patients were enrolled [93–97]. This consideration reduces
the level of our recommendation in comparison with inten-
sive care patients. Caspofungin and micafungin trials included
approximately 10% neutropenic patients [94–96]. The out-
come of these patients was also favourable, and therefore,
both agents received an AIIt recommendation. Anidulafungin
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on the other hand received a marginally weaker recommen-
dation (BIIt) because there were <3% neutropenic patients in
this trial [97]. The extensive usage of echinocandins could
trigger resistance against this class of antifungal agents in the
future because some areas in the world have demonstrated
an increase in C. parapsilosis which usually has higher MICs
compared with other Candida species [98,99]. Despite good
sensitivity results, ﬁrst reports demonstrate caution on the
usage of echinocandins [100,101]. These are some of the
reasons for species discrimination and susceptibility testing
which are highly recommended in these settings.
Fluconazole, once considered gold standard in the treat-
ment of candidaemia received a weaker recommendation
despite positive outcomes in a number of trials [92,102].
These trials are considered out-dated, especially when con-
sidering the risk of the development of resistance. In recent
publications, previous ﬂuconazole or triazole exposure and
gastrointestinal tract surgery are risk factors for ﬂuconazole-
resistant candidaemia. In addition to invasive ventilation,
renal impairment, age >65 years and steroids and triazole
exposure are considered risk factors for death [6,103].
Therefore, ﬂuconazole should only be considered as a step-
down treatment option in neutropenia when the Candida
species isolates demonstrate susceptibility to ﬂuconazole.
Other azoles had only limited data and because of this,
itraconazole and posaconazole in particular, cannot be rec-
ommended for treatment [104]. On the other hand, more
data exist for voriconazole and it may be considered as an
option [105,106]. Despite equal outcome when compared to
micafungin, liposomal amphotericin B received only a BII rec-
ommendation due to its higher nephrotoxicity proﬁle
[96,107]. Due to different toxicity proﬁles and weak data of
other lipid formulations of amphotericin B, a C grading for
the recommendation for treating invasive candidiasis or can-
didaemia is given [108–112]. Extensive nephrotoxicity, con-
secutive higher mortality and other unacceptable toxicity are
factors that make amphotericin B deoxycholate not recom-
mendable for treatment (DII) [30,31] (Table 6).
If patients were receiving ﬂuconazole or liposomal ampho-
tericin B, a switch to an echinocandin might be desirable
(BIIt). Basically, there is no adequately powered randomized
trial for this situation neither for neutropenic patients nor
for stem cell transplant recipients but the identiﬁcation of
the Candida species and susceptibility testing could be helpful
for making a decision (e.g. Candida krusei)(BIII).
In vitro and animal data of antifungal combinations seem to
improve the efﬁcacy of antifungal treatment. In humans, espe-
cially neutropenic patients this outcome is not so clear-cut.
TABLE 5. Treatment of mucosal oropharyngeal or oesophageal candidiasis. Identiﬁcation of Candida species would be
desirable
Diseases Intension Intervention SoR/QoE References
Oropharyngeal Eradication Nystatin suspension (non-neutropenic, mild presentation) CIIt [76,77]
Miconazole buccal BIIt [78]
Fluconazole AI [66,75]
Itraconazole solution BIIt [72–74]
Posaconazole AIIt [69,70]
Voriconazole BIII [71]
Echinocandins (anidulafungin, caspofungin) only in very severe and refractory cases BIII [84,149,150]
Liposomal amphotericin B as an option only in very severe and refractory cases CIII
Oesophageal Eradication Fluconazole AIIt [81,82,151–153]
Itraconazole BIIt [72,80,82]
Posaconazole AIIt [70]
Voriconazole AIII [71]
Topical treatment DIII
Echinocandins (anidulafungin, caspofungin and micafugnin) or liposomal amphotericin
B only in very severe and refractory cases
BIIt [84–90]
TABLE 6. Targeted treatment of invasive candidiasis/candidaemia in patients with malignancies, usually with neutropenia
Intention Intervention SoR QoE Comment References
Morbidity
reduction and
survival
improvement
Fluconazole C IIt Caution regarding resistance. Fluconazole should rather be considered as a
step-down treatment option
[92,93,102]
Itraconazole D III Only abstract in non-neutropenics [154]
Posaconazole D III One case report in a non-neutropenic [104]
Voriconazole C IIt Alternative agent due to better susceptibility data in comparison with
ﬂuconazole but limited clinical data
[105,106]
Amphotericin B colloid dispersion C III Considerable nephrotoxicity [111,112]
Amphotericin B deoxycholate D IIt Unacceptable toxicity [30,31,44,93,94]
Amphotericin B lipid complex C IIa Considerable nephrotoxicity [108,110]
Anidulafungin B IIt <3% of the participants were neutropenic [97]
Caspofungin A IIt 10% of the participants were neutropenic [94,95]
Liposomal amphotericin B B IIt [96,107]
Micafungin A IIt 10% of the participants were neutropenic consider EMA warning [95,96]
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Only a few combinations have been studied without any
improved outcome. Combination of amphotericin B deoxych-
olate and 5-ﬂucytosine is not recommended due to its toxicity
and erratic pharmacokinetics [113–115]. Efungumab and a lipid
formulation amphotericin B are also not recommended
because ﬂaws in the design of the study hampered outcome
[116]. Efungumab is not an approved or marketed drug. The
combination of amphotericin B deoxycholate and ﬂuconazole
was studied as a sequential therapy and did not demonstrate
any improvement to the comparators [105]. There was even
more toxicity in the amphotericin B group despite a median of
only 3 days of amphotericin B deoxycholate exposure.
Another trial assessed whether this combination was antago-
nistic [117]. Due to its similar outcome, this combination can
be considered an option (CIIt). Other combinations were not
studied but the expert opinion is that antifungal combinations
might be useful in severe deep-seated infections (e.g. abdomi-
nal infection, CNS and endocarditis, CIII).
Chronic disseminated candidiasis
Chronic disseminated candidiasis or hepato-splenic candidia-
sis is a very speciﬁc syndrome in patients with malignant dis-
eases. The disease usually occurs after the recovery of
neutrophils due to previous chemotherapy. The diagnosis of
chronic candidiasis is challenging when prior candidaemia has
not been documented. Imaging by ultrasound examination
demonstrates a weaker sensitivity in comparison with CT or
MRI [118–121]. Only one study could show a higher sensitiv-
ity utilizing MRI in comparison with CT [118]. But despite
adequate imaging techniques, the conﬁrmation of the diagno-
sis by biopsy remains troublesome. Histology with culture
positivity is seldom. No comparator trials in regard to
morbidity improvement or survival advantage have been
performed or published. Antigen detection [e.g. mannan/anti-
mannan or 1,3-ß-D-glucan) are probably helpful, but data in
this situation are scarce [122]. Histology requires the use of
special staining (Gomori) and immunohistochemistry and
molecular-genetic workup is highly recommended.
In terms of treatment, only a few case series have been
published [96,123–126]. The experience of treatment is cur-
rently only anecdotal. Lipid formulations of amphotericin B
might be a good choice because of potential accumulation in
the reticulo-endothelial system [127]. Frequently, sequential
approaches are employed empirically, for example liposomal
amphotericin B followed by prolonged treatment of ﬂuconaz-
ole. The disease has been recently considered to be an
inﬂammatory immune reconstitution syndrome [128]. There
are interesting publications that suggest the co-administration
of steroids at the beginning of treatment [129,130]. The
duration of antifungal treatment appears to be at least
8 weeks. Again the use of amphotericin B deoxycholate is
not encouraged (Table 7).
Bioﬁlms and central venous catheters
Central venous catheters (CVC) play a major role in the
care of this patient population. Once inserted, the removal
or replacement might threaten the life of the patient because
of frequently experienced thrombocytopenia. Upon review
of the published data, a negative outcome during therapy by
not removing the central venous catheter early appears only
to occur in the situation where echinocandins were not used
[6,94–97,131,132]. In the recently published trials, where the
central venous catheter was retained, the outcome was simi-
lar but the numbers noted in those trials were low
[94,95,97]. Additionally, these trials demonstrated an equal
outcome in C. parapsilosis disease despite other publications
indicating higher MICs [133,134]. As C. parapsilosis is associ-
ated with catheter infections, removal would be desirable.
On the other hand, if catheter retention is clinical neces-
sary, treatment with an echinocandin remains an option.
Nevertheless, persistence of positive blood cultures for yeast
should prompt removal of a central venous catheter. Velasco
and Bigni [135] saw in their study by multivariate analysis
that comorbidities and neutropenia were independently asso-
ciated with mortality in adults and not CVC removal. In a
trial by Liu et al., early catheter removal is associated with
better survival. In this trial, the retention of the catheter,
high APACHE II score or thrombocytopenia was associated
with a higher mortality rate [131]. Nucci et al. [136] looked
especially on the outcome in terms of CVC removal and
reported no differences between the groups being given ca-
spofungin, micafungin or liposomal amphotericin B. But
TABLE 7. Treatment of chronic disseminated candidiasis
Intention Intervention Duration SoR/QoE Comments Reference
Eradication Fluconazole Reported duration minimum 3 months BIII [125,126] [125,126]
Other azoles (if susceptibility is expected) BIII Lacking data ND
Amphotericin B deoxycholate DIII Toxicity issues [30,31]
Lipid formulations of amphotericin B 8 weeks AIII Better exposure [96,124]
Defervesce Steroid therapy Until defervesce CIII [129,130]
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another work by Andes et al. [137] saw in review of seven
clinical trials that improved survival and greater clinical suc-
cess is associated with the use of an echinocandin and
removal of the CVC. A few in vitro studies indicate that ech-
inocandins penetrate Candida bioﬁlm better than other anti-
fungal agents [138,139]. A more clinically challenging
question is how to handle other implanted hardware, for
example pacemaker, port-a-cath. Unless an association could
be provided, in cases with implanted hardware and with can-
didaemia, retention of the hardware is appropriate but no
published data are available. Unfortunately, no reliable symp-
tom or sign associated with hardware is available (Table 8).
Cytokines, colony-stimulating factors and
granulocyte infusions for the treatment of
invasive candidiasis or candidaemia
The question regarding the use of colony-stimulating factors
or cytokines in the treatment of invasive candidiasis or candi-
daemia remains unanswered. No controlled trials are avail-
able and only anecdotal data from small numbers of patients
exist. As persistent neutropenia is related to treatment fail-
ure, recovery from neutropenia substantiates the efﬁcacy of
antifungal agents [140–142]. Therefore, the use of colony-
stimulating factors appears to be an option (C III). A recent
Cochrane review indicates no mortality differences for all
infections in patients suffering from neutropenia [143]. There
is only a weak recommendation for granulocyte infusions,
but the data are basically from children (CIII) [144–148]. This
treatment might be considered an option in desperate cases.
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